Compare Appian Corp (APPN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs BIO-TECHNE Corp — how do they compare? Appian Corp trades at $35.5 (market cap $2.55B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 4.4× Appian Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | TECH | |
|---|---|---|
Market Cap | $2.55B | $11.24B |
Sector | Technology | Health |
52-Week High | $45.64 | $72.29 |
52-Week Low | $18.72 | $43.31 |
Enterprise Value | $2.68B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) surged 13.91% to $34.64 following strong Q2 2026 earnings that exceeded expectations, with cloud subscription revenue growing 23% year-over-year. The stock trades near its pivot point of $34 with bullish technical signals from moving averages, though RSI levels suggest potential overbought conditions. Revenue growth has accelerated from $617M in 2024 to $727M in 2025, with the company achieving its first profitable year with $1.23M net income after several years of losses.
Appian demonstrates improving fundamentals with consistent revenue growth and recent profitability, though negative equity and high debt levels present risks. Analyst sentiment is mixed with 31.58% buy ratings but a consensus price target of $32.50 below current levels. The AI-driven workflow platform shows strong enterprise adoption, but investors should weigh growth potential against valuation concerns and competitive pressures in the low-code automation space.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
